A prospective study by Su et al. found that higher pre-chemotherapy AMH levels (greater than 0.7 ng/mL) were associated with an earlier resumption of ovarian function (measured by menses) in breast cancer patients undergoing chemotherapy (Su et al. 2014). Here, AMH is linked to breast carcinoma.